Home / Intelligence / Case Studies / Assessment of the Impact of National Guidelines on Uptake of a Biomarker Among HCPs and Payers
Trinity designed staggered quantitative research to assess the impact of national guidelines on uptake of a biomarker among HCPs and payers.
Geographic Scope: 
Client Situation
The client wanted to understand the impact of national physician society guidelines on uptake / acceptance of an innovative biomarker based on developed patient vignettes, and expectations for updates to payer diagnostic testing polices.
Trinity’s Solution
Trinity conducted qualitative research, fielding a survey with physicians and payers, to determine current physician utilization and payer coverage of biomarker diagnostic test and track evolution in payer policies and physician utilization with Wave II of the survey 6 – 12 months later.
Deliverables
- Interim findings of current physician utilization and payer coverage of the biomarker diagnostic test
- Final deliverable presenting the impact of the guidance on physicians and payers and providing recommendations to improve perception of the biomarker
Project Outcomes & Impact
Research findings helped the brand team to understand how the disease landscape will evolve as availability and adoption of the biomarker expands in the market, and then track this evolution on a longitudinal basis.
Related Intelligence
Blog
Maximum Fair Price Round 2: Passing the Baton
On January 20, 2025, CMS announced the set of fifteen drugs targeted for the second round of Maximum Fair Price (MFP) “negotiations” under IRA. With the outcomes of the first price “negotiations” announced only last August, the IRA MFP process is still in its early development and there remains uncertainty over how it will evolve […]
Read More
Blog
Solving the Cell & Gene Therapy Access Puzzle in the U.S.
Cell and gene therapies (CGTs) have ushered in a new era of medicine, offering patients transformative, even potentially curative solutions, with a single treatment. Despite the clinical promise, barriers to patient access remain given administration complexity, gaps in patient outcome evidence and high costs. As cell and gene therapies become available in new indications beyond […]
Read More
Blog
IRA “Negotiations” Price Release: No Big Surprises, But Is the Industry Ready Today and for the Future?
Yesterday, CMS released the results of the first round of “negotiated” prices for the Inflation Reduction Act (IRA).1 The IRA is a historical landmark legislation for the pharmaceutical industry, and the results from these “negotiations” involving 10 of the top Medicare Part D drugs in terms of spend were eagerly awaited by many. Immediately, both […]
Read More